Bristol-Myers Squibb (NY:BMY)

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 08, 2026

Bristol Myers Squibb Announces ZENBEXUSTM (iberdomide) in Combination with Daratumumab and Dexamethasone (ZDd) Demonstrates Superior Progression-Free Survival vs. Standard of Care in Relapsed and Refractory Multiple Myeloma in Phase 3...

Topics Intellectual Property

October 08, 2026

If you are looking for yield and can think long-term, you'll want to consider Bristol Myers Squibb and Realty Income today.

2 High-Yield Stocks to Buy in October (Hint: Bristol Myers Squibb Is One) ↗

October 07, 2026

Bristol-Myers Squibb (NYSE:BMY) Dividend Quality: High Yield, Sustainability Concerns ↗

Topics Bonds Intellectual Property

October 03, 2026

Via Chartmill

Uncover the latest developments among S&P500 stocks in today's session. ↗

October 05, 2026

Via Chartmill

Which S&P500 stocks are moving on Monday? ↗

October 05, 2026

Via Chartmill

These S&P500 stocks are gapping in today's session ↗

October 05, 2026

Via Chartmill

3 Value Stocks We Steer Clear Of

October 05, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

3 Dirt Cheap Dividend Stocks Worth Buying in October ↗

October 04, 2026

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗

Topics Intellectual Property

October 03, 2026

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

AbbVie boasts stronger revenue growth and free cash flow, while Bristol Myers Squibb trades at half the valuation with nearly double the profit margin.

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 01, 2026

Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.

Topics Economy

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale ↗

October 01, 2026

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

October 01, 2026

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

September 30, 2026

Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks

September 29, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS...

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

Topics Artificial Intelligence Intellectual Property

September 29, 2026

Bristol Myers Squibb trades at a fraction of Eli Lilly's valuation while generating substantial free cash flow, but concentration risk and explosive growth tell very different stories.

Pfizer and Bristol Myers Squibb pair big dividends with growing drug pipelines, a rare combination for income-focused pharma investors.

Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗

September 29, 2026

With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.

Topics Intellectual Property

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation ↗

September 29, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Topics Intellectual Property

1 Cash-Producing Stock to Keep an Eye On and 2 Facing Challenges

September 29, 2026

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 27, 2026

Bristol Myers Squibb raised its 2026 sales outlook in July, while Novo Nordisk expects its sales to be flat at best this year, yet Bristol Myers Squibb trades at the lower earnings multiple.

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Pharmaceutical company share prices may suffer, but probably not by as much as some might fear.

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

Topics Bonds Economy

September 25, 2026

Both face patent cliffs and pay generous dividends, but only one of them can tell you where its next wave of growth is coming from.

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗

Topics Intellectual Property Regulatory Compliance

September 24, 2026

Bristol Myers Squibb trades at a steep valuation discount, while Johnson & Johnson's stronger margins and lower debt offer stability. But patent cliffs and litigation risks complicate both cases.

The company's strong pipeline and newer approved drugs should be enough to allay patent expiration concerns.

Topics Intellectual Property

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal uncertainty.

Topics Intellectual Property

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Topics Intellectual Property

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

September 18, 2026

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 17, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS...

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

Topics Artificial Intelligence Intellectual Property

September 17, 2026